# Peri-implant health is associated with low levels of TNF-α

**Authors:** Juliana Prazeres Gonçalves de Castro, Valquiria Quinelato, Luiza dos Anjos Motta, Telma Regina da Silva Aguiar, Aldir Nascimento Machado, Priscila Ladeira Casado

PMC · DOI: 10.1590/0103-644020256205 · 2025-10-24

## TL;DR

The study found that peri-implant health is linked to lower TNF-α levels, and therapy improves health by reducing these levels.

## Contribution

The novel finding is that TNF-α levels decrease with therapy and correlate with improved peri-implant health.

## Key findings

- TNF-α levels decreased significantly after 36 days in both groups, more so in controls.
- Therapy reduced mucositis from 70% to 23%.
- TNF-α levels correlate with improvements in peri-implant health following therapeutic intervention.

## Abstract

This study aimed to assess tumor necrosis factor-alpha (TNF-α) expression in peri-implant crevicular fluid (PICF) of patients receiving peri-implant supportive therapy. Twenty-six participants with implant-supported prostheses, functioning for at least 1 year, were divided into two groups: control (peri-implant health, n=8) and mucositis (peri-implant mucositis, n=18). All underwent clinical and radiographic exams and received non-invasive therapy (mechanical debridement, with ultrasonic scalers to remove calculus and sodium air-abrasive polishing to eliminate soft debris from the implant and prosthetic components + 0.12% chlorhexidine). Timepoints were: Time 1 (initial diagnosis/treatment); Time 2 (15 days post-diagnosis); Time 3 (21 days after). PICF samples collected at each time point analyzed TNF-α levels via ELISA. While clinical parameters showed no group differences, a trend (p=0.07) towards more keratinized gingiva in controls was noted. Significant TNF-α differences were found over time in the control group (p = 0.029, Kruskal-Wallis), with Dunn's test showing T2/T3 differences (p=0.03). The Mucositis group showed no time differences (p=0.96). Over 36 days, no significant difference (p=0.86, Kruskal-Wallis) was found between the control and mucositis groups. TNF-α levels decreased significantly after 36 days in both groups, more so in controls. Therapy reduced mucositis from 70% to 23%. Overall, while TNF-α levels alone may not conclusively differentiate between healthy and mucositis-affected sites in every context, they do appear to correlate with improvements in peri-implant health following therapeutic intervention.

## Linked entities

- **Proteins:** TNF (tumor necrosis factor)
- **Chemicals:** chlorhexidine (PubChem CID 9552079)
- **Diseases:** mucositis (MONDO:0020579)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** Mucositis (MESH:D052016), calculus (MESH:D002137)
- **Chemicals:** chlorhexidine (MESH:D002710), sodium (MESH:D012964)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12551983/full.md

---
Source: https://tomesphere.com/paper/PMC12551983